[{"id":"3641271b-5a0e-409d-997b-5bc0800249e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT06056024","created_at":"2023-09-28T15:10:33.953Z","updated_at":"2025-02-25T14:18:20.983Z","phase":"Phase 1","brief_title":"A Study to Test How Well Different Doses of BI 3706674 Are Tolerated by People With Advanced Cancer in the Stomach and Oesophagus","source_id_and_acronym":"NCT06056024","lead_sponsor":"Boehringer Ingelheim","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS wild-type • RAS wild-type • KRAS G12 • KRAS amplification"],"overall_status":"Recruiting","enrollment":" Enrollment 146","initiation":"Initiation: 12/06/2023","start_date":" 12/06/2023","primary_txt":" Primary completion: 05/26/2027","primary_completion_date":" 05/26/2027","study_txt":" Completion: 05/26/2027","study_completion_date":" 05/26/2027","last_update_posted":"2025-02-18"},{"id":"75cac4e9-35d9-47ec-8b97-13bc0a811821","acronym":"","url":"https://clinicaltrials.gov/study/NCT06130254","created_at":"2023-11-14T16:14:42.662Z","updated_at":"2025-02-25T14:18:29.119Z","phase":"Phase 1","brief_title":"Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers","source_id_and_acronym":"NCT06130254","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lynparza (olaparib) • Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 52","initiation":"Initiation: 01/30/2024","start_date":" 01/30/2024","primary_txt":" Primary completion: 08/25/2030","primary_completion_date":" 08/25/2030","study_txt":" Completion: 08/25/2030","study_completion_date":" 08/25/2030","last_update_posted":"2025-02-10"},{"id":"28d200e6-3d31-4d3c-b1b7-afb8856e7a71","acronym":"","url":"https://clinicaltrials.gov/study/NCT06704724","created_at":"2025-02-25T16:56:42.270Z","updated_at":"2025-02-25T16:56:42.270Z","phase":"Phase 1","brief_title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene","source_id_and_acronym":"NCT06704724","lead_sponsor":"Pfizer","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Avastin (bevacizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • pemetrexed • oxaliplatin • leucovorin calcium • Zumrad (sasanlimab) • PF-07284892"],"overall_status":"Recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/10/2024","start_date":" 12/10/2024","primary_txt":" Primary completion: 01/30/2028","primary_completion_date":" 01/30/2028","study_txt":" Completion: 01/29/2029","study_completion_date":" 01/29/2029","last_update_posted":"2025-02-04"},{"id":"e678f6ac-527c-48a1-b805-9ef0c833b79e","acronym":"IRB00210915","url":"https://clinicaltrials.gov/study/NCT04117087","created_at":"2021-01-18T20:07:26.907Z","updated_at":"2025-02-25T14:28:43.898Z","phase":"Phase 1","brief_title":"Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer","source_id_and_acronym":"NCT04117087 - IRB00210915","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • CD8 • CD4","pipe":" | ","alterations":" KRAS mutation","tags":["KRAS • CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/28/2020","start_date":" 05/28/2020","primary_txt":" Primary completion: 08/08/2025","primary_completion_date":" 08/08/2025","study_txt":" Completion: 08/08/2025","study_completion_date":" 08/08/2025","last_update_posted":"2025-02-03"},{"id":"a739f9bd-9e38-4add-a12a-eef9a483a2ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT06607185","created_at":"2025-02-25T17:53:34.609Z","updated_at":"2025-02-25T17:53:34.609Z","phase":"Phase 1","brief_title":"A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors","source_id_and_acronym":"NCT06607185","lead_sponsor":"Eli Lilly and Company","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Erbitux (cetuximab) • cisplatin • carboplatin • gemcitabine • albumin-bound paclitaxel • pemetrexed • oxaliplatin • irinotecan • leucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 750","initiation":"Initiation: 10/21/2024","start_date":" 10/21/2024","primary_txt":" Primary completion: 01/01/2030","primary_completion_date":" 01/01/2030","study_txt":" Completion: 01/01/2030","study_completion_date":" 01/01/2030","last_update_posted":"2025-01-28"},{"id":"f04191d0-49ef-4557-a5c3-c47df0794683","acronym":"","url":"https://clinicaltrials.gov/study/NCT06782932","created_at":"2025-02-25T19:18:04.732Z","updated_at":"2025-02-25T19:18:04.732Z","phase":"Phase 1/2","brief_title":"Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer","source_id_and_acronym":"NCT06782932","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" CD20","pipe":"","alterations":" ","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • balstilimab (AGEN2034) • AGEN2373 • GVAX Pancreas (allogeneic GM-CSF-secreting tumor cells) • Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 04/01/2025","start_date":" 04/01/2025","primary_txt":" Primary completion: 12/01/2028","primary_completion_date":" 12/01/2028","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-20"},{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"8d686149-a583-41f2-8927-e211fb3a2fb7","acronym":"QTX3034-001","url":"https://clinicaltrials.gov/study/NCT06227377","created_at":"2024-01-26T18:20:28.721Z","updated_at":"2024-07-02T16:35:00.369Z","phase":"Phase 1","brief_title":"QTX3034 in Patients With KRAS G12D Mutation","source_id_and_acronym":"NCT06227377 - QTX3034-001","lead_sponsor":"Quanta Therapeutics","biomarkers":" KRAS","pipe":"","alterations":" ","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Erbitux (cetuximab) • QTX3034"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 02/05/2024","start_date":" 02/05/2024","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2027","study_completion_date":" 04/01/2027","last_update_posted":"2024-05-29"},{"id":"60c799ec-870e-40c7-8ed6-905963014608","acronym":"","url":"https://clinicaltrials.gov/study/NCT05634525","created_at":"2022-12-02T16:57:09.231Z","updated_at":"2025-02-25T14:17:26.709Z","phase":"Phase 1","brief_title":"Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients","source_id_and_acronym":"NCT05634525","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Krazati (adagrasib)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 05/03/2023","start_date":" 05/03/2023","primary_txt":" Primary completion: 11/01/2027","primary_completion_date":" 11/01/2027","study_txt":" Completion: 11/01/2027","study_completion_date":" 11/01/2027","last_update_posted":"2024-05-15"},{"id":"2b7c4292-573a-4f4f-aeb9-0287544f452d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592888","created_at":"2021-01-18T17:39:37.238Z","updated_at":"2024-07-02T16:35:05.451Z","phase":"Phase 1","brief_title":"DC Vaccine in Pancreatic Cancer","source_id_and_acronym":"NCT03592888","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS • HLA-A","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11","tags":["KRAS • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/20/2018","start_date":" 11/20/2018","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-05-07"},{"id":"d557545c-a8fc-4f7f-9d63-eb284cbe8b60","acronym":"AMPLIFY-7P","url":"https://clinicaltrials.gov/study/NCT05726864","created_at":"2023-02-14T18:02:24.073Z","updated_at":"2024-07-02T16:35:05.951Z","phase":"Phase 1/2","brief_title":"A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid Tumors","source_id_and_acronym":"NCT05726864 - AMPLIFY-7P","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • NRAS mutation • KRAS G12D • KRAS G12V • KRAS G12A • KRAS G12 • KRAS G12S • NRAS G12D • NRAS G12 • NRAS G13 • NRAS G12S • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 04/14/2023","start_date":" 04/14/2023","primary_txt":" Primary completion: 11/01/2026","primary_completion_date":" 11/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-05-03"},{"id":"a0f9dd51-d692-4574-b05e-3f5caa78cfd2","acronym":"AMPLIFY-201","url":"https://clinicaltrials.gov/study/NCT04853017","created_at":"2021-04-21T11:53:35.333Z","updated_at":"2024-07-02T16:35:09.637Z","phase":"Phase 1","brief_title":"A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors","source_id_and_acronym":"NCT04853017 - AMPLIFY-201","lead_sponsor":"Elicio Therapeutics","biomarkers":" KRAS • NRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12","tags":["KRAS • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12D • KRAS G12 • NRAS G12D • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ELI-002 7P • Promune (agatolimod)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/04/2021","start_date":" 10/04/2021","primary_txt":" Primary completion: 01/26/2023","primary_completion_date":" 01/26/2023","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-15"},{"id":"3eb84e3a-596a-4eb0-a2c6-ca4c30c42738","acronym":"NCI-2018-01441","url":"https://clinicaltrials.gov/study/NCT03608631","created_at":"2021-01-18T17:44:21.049Z","updated_at":"2024-07-02T16:35:10.185Z","phase":"Phase 1","brief_title":"iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation","source_id_and_acronym":"NCT03608631 - NCI-2018-01441","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed MSC-derived Exosomes with KrasG12D siRNA"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 01/27/2021","start_date":" 01/27/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-11"},{"id":"d64a4376-f3c6-468c-8bab-9e4a850eabdc","acronym":"Argonaut","url":"https://clinicaltrials.gov/study/NCT05480865","created_at":"2022-07-29T15:55:28.505Z","updated_at":"2024-07-02T16:35:21.318Z","phase":"Phase 1","brief_title":"SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation","source_id_and_acronym":"NCT05480865 - Argonaut","lead_sponsor":"Navire Pharma Inc., a BridgeBio company","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lumakras (sotorasib) • BMS-986466"],"overall_status":"Recruiting","enrollment":" Enrollment 85","initiation":"Initiation: 07/06/2022","start_date":" 07/06/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-01"},{"id":"77602bae-c8cf-42ee-afb1-9b4462427822","acronym":"","url":"https://clinicaltrials.gov/study/NCT06078800","created_at":"2023-10-12T22:13:54.839Z","updated_at":"2024-07-02T16:35:33.764Z","phase":"Phase 1","brief_title":"A Study of YL-17231 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT06078800","lead_sponsor":"Shanghai YingLi Pharmaceutical Co. Ltd.","biomarkers":" PD-L1 • KRAS • MSI","pipe":" | ","alterations":" MSI-H/dMMR • KRAS wild-type • RAS wild-type","tags":["PD-L1 • KRAS • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • KRAS wild-type • RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e YL-17231"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/28/2023","start_date":" 09/28/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2023-10-12"},{"id":"754f31b9-2621-4d8e-805c-acb364907f2f","acronym":"GO-005","url":"https://clinicaltrials.gov/study/NCT03953235","created_at":"2021-01-18T19:27:25.774Z","updated_at":"2025-02-25T14:28:22.357Z","phase":"Phase 1/2","brief_title":"A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens","source_id_and_acronym":"NCT03953235 - GO-005","lead_sponsor":"Gritstone bio, Inc.","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12D • KRAS G13D • KRAS G12 • NRAS Q61 • NRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • SLATE-KRAS"],"overall_status":"Completed","enrollment":" Enrollment 39","initiation":"Initiation: 07/18/2019","start_date":" 07/18/2019","primary_txt":" Primary completion: 03/10/2023","primary_completion_date":" 03/10/2023","study_txt":" Completion: 03/10/2023","study_completion_date":" 03/10/2023","last_update_posted":"2023-09-13"},{"id":"fc21c219-c013-4138-9fe8-07a9c22cead0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05013216","created_at":"2021-08-19T14:52:56.438Z","updated_at":"2024-07-02T16:35:38.156Z","phase":"Phase 1","brief_title":"Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer","source_id_and_acronym":"NCT05013216","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1","pipe":" | ","alterations":" KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation","tags":["KRAS • BRCA1 • BRCA2 • ATM • CDKN2A • CD8 • MLH1 • MSH6 • MSH2 • CD4 • EPCAM • PMS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • PALB2 mutation • CDKN2A mutation • MLH1 mutation • PMS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Hiltonol (poly-ICLC) • KRAS peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 04/11/2022","start_date":" 04/11/2022","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2023-09-04"},{"id":"1d901aad-6b7a-454e-9a35-cb2af530433a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04006301","created_at":"2021-01-18T19:41:14.893Z","updated_at":"2024-07-02T16:36:38.986Z","phase":"Phase 1","brief_title":"First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation","source_id_and_acronym":"NCT04006301","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS G12C • KRAS G12","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS G12C • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JNJ-74699157"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 07/26/2019","start_date":" 07/26/2019","primary_txt":" Primary completion: 07/13/2020","primary_completion_date":" 07/13/2020","study_txt":" Completion: 07/13/2020","study_completion_date":" 07/13/2020","last_update_posted":"2020-11-06"},{"id":"6dd064ce-a694-4785-a251-cdfbdd1c7abc","acronym":"","url":"https://clinicaltrials.gov/study/NCT03101839","created_at":"2021-01-18T15:16:55.418Z","updated_at":"2024-07-02T16:36:54.847Z","phase":"Phase 1","brief_title":"Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours","source_id_and_acronym":"NCT03101839","lead_sponsor":"AstraZeneca","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12 • KRAS A146 • KRAS Q61 • KRAS A59 • KRAS K117 • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AZD4785"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 05/15/2017","start_date":" 05/15/2017","primary_txt":" Primary completion: 01/08/2019","primary_completion_date":" 01/08/2019","study_txt":" Completion: 01/08/2019","study_completion_date":" 01/08/2019","last_update_posted":"2019-10-04"}]